



UCB S.A. 60 Allée de la Recherche, B-1070 Brussels (Belgium)

Press Release

For immediate publication

UCB CONFIRMS STRONG QUARTERLY SALES IN THE US XYZAL SELLS MORE THAN ZYRTEC IN EUROPE

Brussels, 19 April 2005 - Following Pfizer's first quarter 2005 earnings release, UCB confirms that Zyrtec strengthened its leadership position as the number one most prescribed branded antihistamine in the US in new prescriptions. The US in-market sales of Zyrtec have reached \$ 342 million over the first 3 months of 2005, showing a 14% increase compared with the same period in 2004.

In Europe, Xyzal confirmed its strong market penetration with a growth rate of 41% during the first quarter of 2005 versus the same period in 2004. Xyzal continues to sell more than Zyrtec in Europe and the recent approval of Xyzal in Persistent Allergic Rhinitis (PER), the first and only medication approved for this indication should fuel continuous growth. Xyzal IMS¹ market share for Europe reached in February 2005, 13.4% compared to 9.4% a year earlier.

About UCB:

UCB (www.ucb-group.com) is a global biopharmaceutical leader with headquarters in Brussels, Belgium, specialising in the fields of central nervous system disorders, allergy and respiratory diseases, immune and inflammatory disorders and oncology. UCB key products are Keppra® (antiepileptic), Xyzal® and Zyrtec® (antiallergics), Nootropil® (cerebral function regulator), Tussionex™ (antitussive) and Metadate™ / Equasym XL™ (attention-deficit/hyperactivity disorder). UCB employs over 8,000 people operating in over 40 countries and achieved revenues of € 2.1 billion (including net sales, royalties, and fees) and an operating profit before amortisation (EBITA) of € 389 million in 2004 (pro-forma IFRS excluding the specialty chemicals activities, divested in February 2005). UCB is listed on Euronext Brussels with a market capitalization of approximately € 5.5 billion.

Information:

Jean-Christophe Donck
VP Corporate Communication
UCB
Tel: +32 (0)2 559 9588
JC.Donck@ucb-group.com

¹ IMS, Total R6A Antihistamine market in €(5 major European Markets - February 2005)